A Twelve-Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-238 (Somatropin) as Compared with Daily Nutropin AQ (Somatropin) in Prepubertal Children with Growth Hormone Deficiency
|Effective start/end date||11/4/08 → 9/11/09|
- Altus Pharmaceuticals Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.